By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it will conduct BRCA testing on patients enrolled in an Abbott Laboratories drug study.

Myriad will perform BRCA1 and BRCA2 mutation testing on patients in the Phase III, multi-center study of an Abbott drug for metastatic breast cancer. The Salt Lake City-based firm said that the agreement is similar to a previous agreement for a Phase II study of the same drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.